Concert Pharmaceuticals

Breakthrough Alopecia Drug Can Regrow An Entire Head of Hair, Study Shows

Oral Medicine CTP-543 Shows Promising Results to Treat Mild to Severe Alopecia After Completing Phase 3 Clinical Trial

Medicine & Technology May 27, 2022

Lexington-based Concert Pharmaceuticals claims that an experimental treatment for alopecia could restore hair in up to 42% of people with severe hair loss. Read on to learn more.

Concert Pharmaceuticals

Oral Medicine CTP-543 Shows Promising Results to Treat Mild to Severe Alopecia After Completing Phase 3 Clinical Trial

Most Popular

How Technology Is Changing the Real Estate Industry?

Nikolay Karpenko Biography, Photo, Career, Accomplishments

How a Plant-Based Diet Can Protect Against Breast Cancer: Insights from Nutrition Research

The Role of AI in the Next Generation of Logistics: Insights from Tobias Waldhecker

China’s Tiangong Space Station to Expand Its Capabilities With New Modules

Recommended Stories

NASA Shuts Down Voyager 2 Science Instrument After 47 Years to Conserve Energy

OpenAI’s Whisper Faces Scrutiny Over Accuracy, Experts Find 'Hallucinated' Text in Transcripts

Martian Ice May Support Microbial Life Beneath Its Surface, New Study Suggests

NASA Astronaut Hospitalized After Returning from Extended Space Mission